A cost-saving analysis of pharmacologic management in osteoporotic fracture prevention among postmenopausal women
Pooled result · Fracture risk, pharmacologic therapy vs placeboResult — go to the resultRelative risk 0.70Authors' conclusion
Pharmacologic therapies, particularly bisphosphonates and hormone therapy, effectively reduce fracture incidence and generate substantial cost savings in high-risk postmenopausal women.
Study context
- Population
- Postmenopausal women; pharmacologic interventions for osteoporotic fracture prevention
- Participants
- 86,411 women30 RCTs
- Comparison
- HRT, bisphosphonates and biologics vs placebo
- Outcome
- Fracture risk reduction and cost savings of pharmacologic management
Methodological detailsrandom-effects model, Medicare data, 10-year projection
- Random-effects model
- Medicare data
- 10-year projection
Pooled result
Fracture risk, pharmacologic therapy vs placebo
Relative risk
0.70
P < 0.001
As reported in the abstract
- HRT reduced fracture risk
- 27%
- Bisphosphonates reduced fracture risk
- 31%
- Biologics reduced fracture risk
- 40%
Further pooled results
Annual net savings at $8600 per fracture
- Bisphosphonates
- $3.35B
- HRT
- $3.01B
- Biologics
- $1.33B
Cumulative cost reduction with HRT · 10 years
- HRT
- $118B
Original publication
A cost-saving analysis of pharmacologic management in osteoporotic fracture prevention among postmenopausal women. Osteoporos Int. Published 1 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →